A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia.

Trial Profile

A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Quizartinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ambit Biosciences Corporation; Astellas Pharma; Daiichi Sankyo Inc
  • Most Recent Events

    • 17 Jun 2018 Results of a post-hoc analysis from NCT01565668 and NCT00989261 studies presented at the 23rd Congress of the European Haematology Association.
    • 06 Jun 2018 Results published in the Blood Journal.
    • 05 Jun 2018 Results of post hoc explopratory analysis of two phase 2 trials (NCT01565668; NCT00989261) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top